Published in Law and Health Weekly, January 12th, 2004
MS-325 is, according to the company, the first magnetic resonance blood pool contrast agent which has successfully completed clinical development for vascular imaging.
"MS-325 offers a real breakthrough in the field of vascular imaging. It is an innovative MRA contrast agent for the detection of structural abnormalities, such as stenosis and aneurysm, in patients with known or suspected vascular disease," said Michael...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law and Health Weekly